Comparisons of Guideline-Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry)

Steinberg, Benjamin A.; Steg, P. Gabriel; Bhatt, Deepak L.; Fonarow, Gregg C.; Zeymer, Uwe; Cannon, Christopher P.; REACH Registry Investigators,

doi:10.1016/j.amjcard.2006.12.039

« Previous Next »American Journal of Cardiology
Volume 99, Issue 9 , Pages 1212-1215, 1 May 2007

Comparisons of Guideline-Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry)

Benjamin A. Steinberg, BA
- Thrombolysis In Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
P. Gabriel Steg, MD
- Hôpital Bichat-Claude Bernard, Services de Cardiologie, Pairs, France
- Dr. Steg has received honoraria for consulting or lectures from AstraZeneca, Bristol-Myers Squibb, Merck-Sharp Dohme, Nycomed, GlaxoSmithKline, Nycomed, Sanofi-Aventis, Servier, Takeda. His department has received a research grant from Sanofi-Aventis.
Deepak L. Bhatt, MD
- Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, Ohio
- Dr. Bhatt has received honoraria for consulting on scientific advisory boards from AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly, GlaxoSmithKline, Millennium, Paringenix, PDL, Sanofi-Aventis, Schering Plough, The Medicines Company and honoraria for lectures from Bristol-Myers Squibb, Sanofi-Aventis, and The Medicines Company.
Gregg C. Fonarow, MD
- David Geffen School of Medicine, UCLA, Los Angeles, California
- Dr. Fonarow has received research grants from GlaxoSmithKline, Pfizer, and Amgen. He is on the speaker’s bureau or has received honoraria from Sanofi-Aventis, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Merck, Schering-Plough, AstraZeneca, Amgen, and Biosite. He is a consultant for Sanofi-Aventis, GlaxoSmithKline, Pfizer, Merck, Schering Plough, and Bristol-Myers Squibb.
Uwe Zeymer, MD
- Herzzentrum Ludwigshafen, Medizinische Klinik II, Ludwigshafen, Germany.
- Dr. Zeymer has received research grants and honoraria for speaker bureau meetings from Bristol Myers Squibb, Sanofi Aventis, and Boehringer Ingelheim.
Christopher P. Cannon, MD
- Thrombolysis In Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
- Dr. Cannon has received research grant support from Merck, AstraZeneca, Schering-Plough, and Accumetrics. He serves on advisory boards as a consultant with AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Schering-Plough, Pfizer, and Sanofi-Aventis.
- Corresponding author: Tel: 617-278-0146; fax: 617-734-7329.
REACH Registry Investigators
- The REACH Registry is sponsored by Sanofi-Aventis, Paris, France; Bristol-Myers Squibb, New York, New York; and the Waksman Foundation, Tokyo, Japan.